Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells

International Journal of Cancer. Journal International Du Cancer
Uwe ReuschSergey M Kipriyanov

Abstract

To develop an effective antitumor immunotherapy for B-lineage non-Hodgkin's lymphoma, we constructed a tetravalent tandem diabody (tanDb) specific for both human CD19 (B-cell marker) and CD3 (T-cell antigen). Here, we report the effective killing of malignant primary B cells from patients with B-cell chronic lymphocytic leukemia (B-CLL) by autologous T cells induced by tanDb at very low E:T ratios. Mononuclear cells from patients with B-CLL were cultured with bispecific antibody fragments in either the presence or absence of monospecific anti-CD28 antibody. Use of tetravalent tanDbs caused almost quantitative elimination of malignant B cells from the blood samples of 19 patients and some cytotoxic activity in 3 of 23 analyzed cases. In contrast, the structurally similar but bivalent diabody and single-chain diabody demonstrated nearly no antitumor activity in an autologous system. tanDb-induced activation and proliferation of T cells occurred only in the presence of CD19+ target cells. Expression of the B7-1 (CD80) and B7-2 (CD86) molecules on the surface of leukemia cells made unnecessary the additional CD28-costimulation of T cells. When only a few tanDb molecules were present, the effect of CD28 costimulation on T-cell activ...Continue Reading

References

Oct 19, 1995·The New England Journal of Medicine·C Rozman, E Montserrat
Jul 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·P HolligerG Winter
Jul 8, 1997·Proceedings of the National Academy of Sciences of the United States of America·M A GhetieE S Vitetta
Aug 4, 1998·International Journal of Cancer. Journal International Du Cancer·S M KipriyanovM Little
Aug 26, 1998·Proceedings of the National Academy of Sciences of the United States of America·P Scheipers, H Reiser
Apr 21, 1999·Current Opinion in Cell Biology·C A Chambers, J P Allison
Oct 8, 1999·Journal of Molecular Biology·S M KipriyanovM Little
Jul 6, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·B CochloviusM Little
Aug 1, 2000·Immunology Today·A B van SprielJ G van De Winkel
Aug 25, 2001·Blood·D HuhnUNKNOWN German Chronic Lymphocytic Leukemia Study Group
Feb 6, 2002·The Journal of Clinical Investigation·Kenneth A Frauwirth, Craig B Thompson
Jun 22, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sergey M KipriyanovMelvyn Little
Sep 5, 2002·International Journal of Cancer. Journal International Du Cancer·Torsten DreierPatrick A Baeuerle
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K R RaiL Brettman
Nov 26, 2002·Hematology·Neil E KayThomas Lin
Apr 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·F Stephen HodiGlenn Dranoff
Apr 29, 2003·British Journal of Haematology·Thomas SieberFolke Schriever
Apr 30, 2003·Nature Immunology·Christina M Trambas, Gillian M Griffiths
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Blanche Mavromatis, Bruce D Cheson
May 9, 2003·Reviews in Clinical and Experimental Hematology·Francesca R MauroRobin Foa
Jun 18, 2003·Trends in Immunology·David M SansomYong Zheng
Jun 24, 2003·Journal of Molecular Biology·Sergey M KipriyanovMelvyn Little
Jun 27, 2003·Proceedings of the National Academy of Sciences of the United States of America·Giao Q PhanSteven A Rosenberg
Feb 14, 2004·Blood·Freda K Stevenson, Federico Caligaris-Cappio
Nov 10, 2004·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Sanjeev KrishnaRichard K Haynes

❮ Previous
Next ❯

Citations

Jan 19, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Philippe Fournier, Volker Schirrmacher
Oct 8, 2013·Trends in Biotechnology·Hannah ByrneRichard J O'Kennedy
Sep 6, 2008·Cancer Biotherapy & Radiopharmaceuticals·Marcus P KellyAndrew M Scott
Jan 22, 2005·Acta Pharmacologica Sinica·Roland E Kontermann
Nov 5, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Lawrence G Lum, Archana Thakur
Mar 1, 2009·Immunotherapy·Nurit Hollander
Jul 30, 2005·Expert Opinion on Biological Therapy·Volker Schirrmacher
Sep 19, 2012·Journal of Molecular Biology·Fabrice Le GallSergej M Kiprijanov
Jun 11, 2011·Best Practice & Research. Clinical Haematology·Tom van Meerten, Anton Hagenbeek
Mar 11, 2016·Current Opinion in Immunology·Eugene A ZhukovskyMarcela V Maus
May 22, 2008·British Journal of Haematology·Ilse HoutenbosArjan A van de Loosdrecht
Jan 12, 2005·Protein Expression and Purification·Dipankar DasMavanur R Suresh
Sep 10, 2014·Critical Reviews in Oncology/hematology·Roeland LamerisHans J van der Vliet
Mar 12, 2015·Drug Discovery Today·Natalia Nuñez-PradoLuis Álvarez-Vallina
Jan 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alfonso Quintás-CardamaSusan O'Brien

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.